13.01.2017 • NewsDede WillamsAcidsArkema

Arkema Upgrading US Acrylic Acid Units

(c) Arkema
(c) Arkema

French specialty chemicals producer Arkema is spending $90 million on upgrading technology at its Clear Lake, Texas site acrylic acid production units. When the two production units of 45,000 t/y each are merged into one larger 90,000 t/y reactor equipped with state-of-the-art technology, the Texas site will be “among the most competitive in North America while meeting growing demand in the region,” the company said.

The new facility is due to go on stream in mid-2019. At completion, Clear Lake's total acrylic acid production capacity will be 270 t/y. While construction is in progress, Arkema said it will supply customers from other facilities in the US, Europe and Asia. 

With this investment Arkema, said, it will cement its position as North America’s second largest producer of acrylic acid, supplying growing markets such as superabsorbents, coatings and adhesives an polymers for water treatment, as well as oil and gas recovery. The French company restructured other part of its US acrylics business between 2012 and 2014.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.